151 related articles for article (PubMed ID: 22208485)
1. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.
Jennings LJ; Smith FA; Halling KC; Persons DL; Kamel-Reid S;
Arch Pathol Lab Med; 2012 Jan; 136(1):33-40. PubMed ID: 22208485
[TBL] [Abstract][Full Text] [Related]
2. Standardisation of molecular monitoring for chronic myeloid leukaemia.
Cross NC
Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
[TBL] [Abstract][Full Text] [Related]
3. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use.
Jones CD; Yeung C; Zehnder JL
Am J Clin Pathol; 2003 Jul; 120(1):42-8. PubMed ID: 12866371
[TBL] [Abstract][Full Text] [Related]
5. Real-time quantitative reverse transcriptase polymerase chain reaction.
Fan H; Robetorye RS
Methods Mol Biol; 2010; 630():199-213. PubMed ID: 20300999
[TBL] [Abstract][Full Text] [Related]
6. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
7. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in chronic myeloid leukaemia patients.
Hochhaus A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):159-78. PubMed ID: 11987922
[TBL] [Abstract][Full Text] [Related]
9. A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation.
Schumacher JA; Szankasi P; Bahler DW; Ho AK; Kelley TW
J Clin Pathol; 2011 Jul; 64(7):618-25. PubMed ID: 21486895
[TBL] [Abstract][Full Text] [Related]
10. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
11. Molecular methods in diagnosis and monitoring of haematological malignancies.
Yeung DT; Parker WT; Branford S
Pathology; 2011 Oct; 43(6):566-79. PubMed ID: 21881536
[TBL] [Abstract][Full Text] [Related]
12. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Xpert
Dominy KM; Simon IM; Sorouri-Khorashad J
Int J Lab Hematol; 2021 Feb; 43(1):e31-e34. PubMed ID: 32990400
[No Abstract] [Full Text] [Related]
14. Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing.
Griffiths M; Patton SJ; Grossi A; Clark J; Paz MF; Labourier E;
Arch Pathol Lab Med; 2015 Apr; 139(4):522-9. PubMed ID: 25061833
[TBL] [Abstract][Full Text] [Related]
15. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
16. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Ross DM; Watkins DB; Hughes TP; Branford S
Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
[TBL] [Abstract][Full Text] [Related]
17. LightCycler technology for the quantitation of bcr/abl fusion transcripts.
Kreuzer KA; Lass U; Bohn A; Landt O; Schmidt CA
Cancer Res; 1999 Jul; 59(13):3171-4. PubMed ID: 10397261
[TBL] [Abstract][Full Text] [Related]
18. [Detection of bcr/abl fusion gene in chronic myeloid leukemia by fluorescence in situ hybridization and nested reverse transcription polymerase chain reaction].
Wu B; Zhou SY; Liu XL; Song LL; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2003 May; 24(5):235-7. PubMed ID: 12859872
[TBL] [Abstract][Full Text] [Related]
19. [Genetic diagnosis of chronic myeloid leukemia].
Kato C; Naoe T
Nihon Rinsho; 2001 Dec; 59(12):2336-41. PubMed ID: 11766335
[TBL] [Abstract][Full Text] [Related]
20. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
